Undervalued Stocks
HRMY is currently part of our Undervalued Stocks screen, meaning it meets strict valuation and quality criteria
HARMONY BIOSCIENCES HOLDINGS (HRMY) Stock Price & Overview
NASDAQ:HRMY • US4131971040
Current stock price
29.5 USD
+0.45 (+1.55%)
Last:
The current stock price of HRMY is 29.5 USD. Today HRMY is up by 1.55%. In the past month the price increased by 5.22%. In the past year, price increased by 2.07%.
HRMY Key Statistics
52-Week Range25.52 - 40.87
Current HRMY stock price positioned within its 52-week range.
1-Month Range26.34 - 29.5
Current HRMY stock price positioned within its 1-month range.
- Market Cap
- 1.707B
- P/E
- 10.89
- Fwd P/E
- 8.04
- EPS (TTM)
- 2.71
- Dividend Yield
- N/A
HRMY Stock Performance
Today
+1.55%
1 Week
+4.84%
1 Month
+5.22%
3 Months
-19.80%
Longer-term
6 Months +12.16%
1 Year +2.07%
2 Years -6.02%
3 Years -9.89%
5 Years -0.85%
10 Years N/A
HRMY Stock Chart
HRMY Stock Screens
HRMY currently appears in the following ChartMill screener lists.
High ROIC Stocks
HRMY is currently part of our High ROIC Stocks screen, indicating it generates strong returns on invested capital.
High Free Cash Flow Stocks
HRMY is currently part of our High Free Cash Flow Stocks screen, indicating it generates strong cash flows relative to its price.
Low P/E Stocks
HRMY is currently part of our Low P/E Stocks screen, indicating it cheap while it also meets financial health criteria.
Value Stocks with Strong Balance Sheets
HRMY is currently part of our value stocks with Strong Balance Sheets screen, indicating it cheap while meeting strict financial health and debt criteria.
Revenue Growth Leaders
HRMY is part of our revenue growth leaders stock screen, indicating it has strong recent and multi-year revenue growth.
Highest Analyst Upside Stocks
HRMY is part of our highest analyst upside stock list, indicating analysts have a price target way above the current price.
HRMY Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to HRMY. When comparing the yearly performance of all stocks, HRMY is a bad performer in the overall market: 79.35% of all stocks are doing better.
Chartmill TA Rating
Chartmill Setup Rating
HRMY Fundamental Analysis
ChartMill assigns a fundamental rating of 7 / 10 to HRMY. HRMY has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
HRMY Earnings
On February 24, 2026 HRMY reported an EPS of 0.38 and a revenue of 243.78M. The company missed EPS expectations (-58.44% surprise) and missed revenue expectations (-0.58% surprise).
Next Earnings DateMay 5, 2026
Last Earnings DateFeb 24, 2026
PeriodQ4 / 2025
EPS Reported$0.38
Revenue Reported243.776M
EPS Surprise -58.44%
Revenue Surprise -0.58%
HRMY Forecast & Estimates
17 analysts have analysed HRMY and the average price target is 42.75 USD. This implies a price increase of 44.91% is expected in the next year compared to the current price of 29.5.
For the next year, analysts expect an EPS growth of 35.46% and a revenue growth 17.86% for HRMY
Analysts
Analysts75.29
Price Target42.75 (44.92%)
EPS Next Y35.46%
Revenue Next Year17.86%
HRMY Groups
Sector & Classification
HRMY Financial Highlights
Over the last trailing twelve months HRMY reported a non-GAAP Earnings per Share(EPS) of 2.71. The EPS increased by 7.97% compared to the year before.
Income Statements
Revenue(TTM)868.45M
Net Income(TTM)158.69M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 18.27% | ||
| ROA | 12.48% | ||
| ROE | 18.24% | ||
| Debt/Equity | 0.17 |
Chartmill High Growth Momentum
EPS Q2Q%-55.29%
Sales Q2Q%21.12%
EPS 1Y (TTM)7.97%
Revenue 1Y (TTM)21.51%
HRMY Ownership
Ownership
Inst Owners89.73%
Shares57.87M
Float50.27M
Ins Owners0.69%
Short Float %15.21%
Short Ratio8.28
HRMY Competitors/Peers
The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 26.77 | 878.257B | ||
| JNJ | JOHNSON & JOHNSON | 20.33 | 573.153B | ||
| MRK | MERCK & CO. INC. | 23.27 | 297.058B | ||
| PFE | PFIZER INC | 9.09 | 155.52B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.16 | 118.543B | ||
| ZTS | ZOETIS INC | 16.95 | 50.689B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.43 | 27.937B | ||
| VTRS | VIATRIS INC | 5.55 | 16.104B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 22.92 | 11.863B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 9.122B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.497B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 6.072B | ||
| CORT | CORCEPT THERAPEUTICS INC | 80.64 | 4.606B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About HRMY
Company Profile
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company, which engages in the provision of development and commercialization of therapies for the treatment of neurological disorders. The company is headquartered in Plymouth Meeting, Pennsylvania and currently employs 293 full-time employees. The company went IPO on 2020-08-19. The company is focused on developing and commercializing therapies for patients living with rare neurological diseases as well as patients living with other neurological diseases who have unmet medical needs. Its product, WAKIX (pitolisant), is a first-in-class molecule with a novel mechanism of action designed to enhance histamine signaling in the brain by binding to H3 receptors. WAKIX was developed for the treatment of excessive daytime sleepiness (EDS) in pediatric patients, six years and older, with narcolepsy. HBS-102, an investigational compound, which is a melanin-concentrating hormone receptor 1 (MCHR1) antagonist. ZYN002 is an investigational drug product in development for the potential treatment of behavioral symptoms associated with Fragile X syndrome (FXS) and 22q11.2 deletion syndrome (22q). The company also focused on the rare epilepsy franchise in its expanding late-stage pipeline of CNS assets: EPX-100 and EPX-200.
Company Info
IPO: 2020-08-19
HARMONY BIOSCIENCES HOLDINGS
630 W Germantown Pike, Suite 215
Plymouth Meeting PENNSYLVANIA 19462 US
CEO: John C. Jacobs
Employees: 293
Phone: 13026587581
HARMONY BIOSCIENCES HOLDINGS / HRMY FAQ
Can you describe the business of HARMONY BIOSCIENCES HOLDINGS?
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company, which engages in the provision of development and commercialization of therapies for the treatment of neurological disorders. The company is headquartered in Plymouth Meeting, Pennsylvania and currently employs 293 full-time employees. The company went IPO on 2020-08-19. The company is focused on developing and commercializing therapies for patients living with rare neurological diseases as well as patients living with other neurological diseases who have unmet medical needs. Its product, WAKIX (pitolisant), is a first-in-class molecule with a novel mechanism of action designed to enhance histamine signaling in the brain by binding to H3 receptors. WAKIX was developed for the treatment of excessive daytime sleepiness (EDS) in pediatric patients, six years and older, with narcolepsy. HBS-102, an investigational compound, which is a melanin-concentrating hormone receptor 1 (MCHR1) antagonist. ZYN002 is an investigational drug product in development for the potential treatment of behavioral symptoms associated with Fragile X syndrome (FXS) and 22q11.2 deletion syndrome (22q). The company also focused on the rare epilepsy franchise in its expanding late-stage pipeline of CNS assets: EPX-100 and EPX-200.
What is the stock price of HARMONY BIOSCIENCES HOLDINGS today?
The current stock price of HRMY is 29.5 USD. The price increased by 1.55% in the last trading session.
Does HRMY stock pay dividends?
HRMY does not pay a dividend.
How is the ChartMill rating for HARMONY BIOSCIENCES HOLDINGS?
HRMY has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 7 out of 10.
Which stock exchange lists HRMY stock?
HRMY stock is listed on the Nasdaq exchange.
Is HARMONY BIOSCIENCES HOLDINGS (HRMY) expected to grow?
The Revenue of HARMONY BIOSCIENCES HOLDINGS (HRMY) is expected to grow by 17.86% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the market capitalization of HRMY stock?
HARMONY BIOSCIENCES HOLDINGS (HRMY) has a market capitalization of 1.71B USD. This makes HRMY a Small Cap stock.